DE602006009786D1 - Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten - Google Patents

Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten

Info

Publication number
DE602006009786D1
DE602006009786D1 DE602006009786T DE602006009786T DE602006009786D1 DE 602006009786 D1 DE602006009786 D1 DE 602006009786D1 DE 602006009786 T DE602006009786 T DE 602006009786T DE 602006009786 T DE602006009786 T DE 602006009786T DE 602006009786 D1 DE602006009786 D1 DE 602006009786D1
Authority
DE
Germany
Prior art keywords
mcp
ccr2
molecules
treatment
associated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006009786T
Other languages
English (en)
Inventor
Nathan Karin
Gizi Wildbaum
Yaniv Zohar
Liat Izhak
Uri Weinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rappaport Family Institute for Research in the Medical Sciences
Original Assignee
Rappaport Family Institute for Research in the Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rappaport Family Institute for Research in the Medical Sciences filed Critical Rappaport Family Institute for Research in the Medical Sciences
Publication of DE602006009786D1 publication Critical patent/DE602006009786D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006009786T 2005-04-15 2006-04-10 Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten Active DE602006009786D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67147605P 2005-04-15 2005-04-15
PCT/IL2006/000454 WO2006109301A2 (en) 2005-04-15 2006-04-10 Molecules and methods of using same for treating mcp-1/ccr2 associated diseases

Publications (1)

Publication Number Publication Date
DE602006009786D1 true DE602006009786D1 (de) 2009-11-26

Family

ID=36688002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006009786T Active DE602006009786D1 (de) 2005-04-15 2006-04-10 Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten

Country Status (11)

Country Link
US (1) US8388962B2 (de)
EP (1) EP1871798B1 (de)
JP (1) JP2008535909A (de)
CN (1) CN101160323A (de)
AT (1) ATE445644T1 (de)
AU (1) AU2006233927A1 (de)
CA (1) CA2597789A1 (de)
DE (1) DE602006009786D1 (de)
ES (1) ES2333358T3 (de)
MX (1) MX2007010484A (de)
WO (1) WO2006109301A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006009786D1 (de) 2005-04-15 2009-11-26 Rappaport Family Inst For Res Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
WO2007100920A2 (en) * 2006-03-01 2007-09-07 The Regents Of The University Of Michigan Diagnosis and treatment of prostate cancer
EP2193805A4 (de) * 2007-08-24 2013-09-04 Univ Keio Immunsuppressions-entwöhnungsmittel mit tumorzellen und dieses verwendende antitumorale mittel
CN102370981B (zh) * 2010-08-11 2014-07-16 中国科学院上海生命科学研究院 防治神经退行性疾病的试剂和方法
CN105530945A (zh) * 2013-08-06 2016-04-27 国立大学法人九州大学 有机酸聚合物作为有效组分的、预防或抑制癌细胞生存的药物
NO2776305T3 (de) * 2014-04-23 2018-01-27
CN107362353A (zh) * 2016-05-11 2017-11-21 上海长海医院 一种去势抵抗的***癌相关的药物靶点及其应用
KR102308102B1 (ko) * 2018-05-18 2021-10-07 가톨릭대학교 산학협력단 Ccr2를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물
KR102308099B1 (ko) * 2019-11-15 2021-10-01 가톨릭대학교 산학협력단 Soluble CCR2 발현 유도된 줄기세포를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물
WO2021095946A1 (ko) * 2019-11-15 2021-05-20 가톨릭대학교 산학협력단 Ccr2를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019436A1 (en) * 1994-01-13 1995-07-20 The Regents Of The University Of California Mammalian monocyte chemoattractant protein receptors
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
WO2001058916A2 (en) * 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
FR2828102B1 (fr) * 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1648936B1 (de) 2003-07-24 2007-06-06 Amgen Inc. Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
IL157398A0 (en) 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
GB2423472A (en) 2003-12-11 2006-08-30 Univ Yale Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
US20050215543A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
DE602006009786D1 (de) 2005-04-15 2009-11-26 Rappaport Family Inst For Res Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten

Also Published As

Publication number Publication date
EP1871798B1 (de) 2009-10-14
WO2006109301A2 (en) 2006-10-19
ES2333358T3 (es) 2010-02-19
US20110033521A1 (en) 2011-02-10
EP1871798A2 (de) 2008-01-02
WO2006109301A3 (en) 2006-12-07
ATE445644T1 (de) 2009-10-15
CN101160323A (zh) 2008-04-09
JP2008535909A (ja) 2008-09-04
CA2597789A1 (en) 2006-10-19
MX2007010484A (es) 2007-10-15
AU2006233927A1 (en) 2006-10-19
US8388962B2 (en) 2013-03-05

Similar Documents

Publication Publication Date Title
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
ATE545418T1 (de) Zusammensetzungen und kits zur behandlung von influenza
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
DE602004001134D1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition